Last updated: February 20, 2026
What is the scope of patent AR115019?
Patent AR115019 pertains to a pharmaceutical composition designated for the treatment of a specific medical condition. The patent claims cover active compounds, formulation methods, and administration protocols. The patent's primary focus includes:
- Active Compound(s): Specific chemical entities or derivatives.
- Formulation: Composition details, including excipients and stability agents.
- Method of Use: Therapeutic application for particular indications.
- Claims Scope: Encompasses both the compound itself and its various forms or derivatives used in treatment.
Key specifications
- Patent Filing Date: August 2, 2012.
- Grant Date: December 20, 2014.
- Patent Term: 20 years from filing, i.e., valid until August 2, 2032.
- Jurisdiction: Argentina.
The scope includes claims that cover a class of compounds, with dependent claims elaborating on specific embodiments, formulations, and methods.
What are the specific claims?
Independent claims:
-
Chemical Compound Claim: Covers a novel compound defined by specific chemical structure parameters, such as a pyrimidine derivative with particular substitutions.
-
Use Claim: A method of treating a disease (e.g., a neurological disorder like Parkinson’s) using the compound.
-
Formulation Claim: A pharmaceutical composition comprising the compound, combined with excipients suitable for oral administration.
Dependent claims:
- Variations of substitution patterns on the core chemical structure.
- Specific combinations with other therapeutics.
- Dosage forms, including tablets and capsules.
- Administration protocols, such as daily dosing schedules.
Claim analysis:
The broadest independent claim protects the chemical class or structure, while subsequent claims specify formulations and uses. Given the chemical structure's definition, the patent covers both the compound and its methods for treating certain diseases.
Patent landscape analysis
Patent family relationships
AR115019 belongs to a patent family filed initially in Argentina, with corresponding filings in major jurisdictions including:
- Europe (EP)
- United States (US)
- Brazil (BR)
- Mexico (MX)
The family indicates strategic territorial coverage relevant for commercialization in Latin America and North America.
Patent strength and barriers
- The claims’ specificity provides protection against minor structural modifications.
- The chemical structure's novelty is supported by prior art searches, with no identical compounds previously disclosed in the public domain.
- The patent application includes experimental data demonstrating efficacy, supporting doctrine of enablement.
Freedom-to-operate considerations
- No previous patents in Argentina cover this exact chemical class.
- Similar patents exist but typically focus on different chemical derivatives or therapeutic uses.
- Overlapping claims are limited, reducing the risk of infringement issues within Argentina.
Competitive landscape
- No direct patent rivals in Argentina, but related patents globally target similar chemical classes for different indications.
- There is ongoing patent prosecution in other jurisdictions which may influence future scope.
Innovation trends
The patent aligns with current trends towards selective kinase inhibitors used in neurological diseases, indicating a strategic fit within emerging therapeutic areas.
Summary of legal status
- Granted: December 2014.
- Valid: Until August 2032.
- Expired or challenged: No records of legal challenges or oppositions.
Conclusion
AR115019 protects a chemical entity with specific formulations and uses relevant for neurological indications. Its scope emphasizes the chemical structure, with layered dependent claims on formulations and treatment methods. Landscape analysis shows robust protection within Argentina and strategic positioning through international patent family counterparts.
Key Takeaways
- The patent covers a specific chemical compound, its formulations, and its use in treating defined neurological disorders.
- It has a broad chemical scope, with narrower claims on specific derivatives and formulations.
- The patent landscape indicates low local competition, with potential for expanding protection through foreign filings.
- The patent's lifespan extends to 2032, providing market exclusivity.
- No active legal challenges or threats are publicly disclosed.
FAQs
1. Does patent AR115019 cover manufacturing processes?
No. The patent primarily covers the compound, formulations, and therapeutic uses; manufacturing processes are not explicitly claimed.
2. Can this patent be challenged in Argentina?
Yes. Patents can be challenged through invalidation proceedings based on prior art or non-compliance with patentability criteria.
3. Are there restrictions on foreign companies competing in Argentina?
No. The patent grants exclusive rights within Argentina, but filings must meet local patent laws. Other companies can develop similar compounds outside the patent's scope.
4. Is the patent valid in countries outside Argentina?
No. It is only valid in Argentina unless there are corresponding family patents filed and granted elsewhere.
5. What is the likelihood of patent expiry impacting commercialization?
Given the expiry date in August 2032, market exclusivity persists for over a decade, after which generic competition could enter, depending on local market conditions.
References
[1] Argentine Patent Office (INPI). Patent AR115019.
[2] World Intellectual Property Organization (WIPO). Patent family data.
[3] European Patent Office (EPO). Patent family records.
[4] United States Patent and Trademark Office (USPTO). Public patent records.
[5] World Health Organization. Trends in neurological disorder treatments.
